Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Dec;15(6):866-875.
doi: 10.1007/s11764-020-00979-4. Epub 2021 Jan 9.

Social support as a moderator of healthcare adherence and distress in long-term hematopoietic cell transplantation survivors

Kristina Holmegaard Nørskov  1 , Jean C Yi  2 , Marie-Laure Crouch  2 , Allison Stover Fiscalini  3 , Mary E D Flowers  2   4 , Karen L Syrjala  2   4
Affiliations
Randomized Controlled Trial

Social support as a moderator of healthcare adherence and distress in long-term hematopoietic cell transplantation survivors

Kristina Holmegaard Nørskov et al. J Cancer Surviv. 2021 Dec.

Erratum in

Abstract

Background: Treatment with hematopoietic cell transplantation (HCT) has potentially severe effects on physical and psychosocial functioning. Poor social support has been linked with physical morbidity and mortality as well as psychological distress in HCT survivors. This study tested a theory-driven hypothesis that social support buffers adverse effects of health stressors of comorbidities and graft-versus-host disease (cGVHD) on distress and adherence to recommended healthcare among long-term HCT survivors.

Methods: This cross-sectional study analyzed baseline data from a randomized controlled trial in adult survivors 3-18 years post-HCT. Data included medical records and patient-reported outcomes including cancer and treatment distress (CTXD), healthcare adherence (HCA), comorbidity index, cGVHD, ENRICHD Social Support Instrument (ESSI), Social Activity Log, and Health Self-Efficacy. We tested hypothesized models for HCA and CTXD using blocked hierarchical linear regressions.

Results: Among the 781 HCT survivors completing baseline assessment, 38% had > 3 comorbidities, 8% had moderate-severe cGVHD, 30% reported low social support, 30% reported elevated distress, and 49% reported low healthcare adherence. Social support and self-efficacy were directly related to both adherence and distress. Regression models supported the hypothesized moderated relationships for distress but not for healthcare adherence.

Conclusions: The two tested models confirm that the health stressors of comorbidities and cGVHD are moderated by better social support and self-efficacy in their associations with lower distress but without moderating effects for healthcare adherence.

Implications for cancer survivors: Social support and self-efficacy confer protective benefits on healthcare adherence and psychological distress. Interventions are needed that focus on maintaining social networks or finding new networks if necessary.

Clinical trial registration number: NCT00799461.

Keywords: Adherence; Cancer survivor; Distress; Hematopoietic stem cell transplantation; Self-efficacy; Social support.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Hypothesized conceptual model of the role of social support in healthcare adherence and distress for cancer survivors. As tested in this study, this model is based on the “buffering hypothesis” (Cohen & Willis 1985) and posits that social support protects people from the potential adverse effects of stressful events, thereby having beneficial influences on health outcomes. Note that although the diagram is displayed sequentially in the order of blocks entered into the model, the measures for this study, other than covariates, were collected concurrently
See this image and copyright information in PMC

References

    1. Hahn T, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski JL, Hale GA, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31(19):2437–49. 10.1200/jco.2012.46.6193. - DOI - PMC - PubMed
    1. McCarthy PL Jr, Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995–2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant. 2013;19(7):1116–23. 10.1016/j.bbmt.2013.04.027. - DOI - PMC - PubMed
    1. Martin PJ, Counts GW Jr, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011–6. 10.1200/jco.2009.25.6693. - DOI - PMC - PubMed
    1. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16): 2230–9. 10.1200/jco.2010.33.7212. - DOI - PMC - PubMed
    1. Bevans M, El-Jawahri A, Tierney DK, Wiener L, Wood WA, Hoodin F, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: the patient-centered outcomes working group report. Biol Blood Marrow Transplant. 2017;23(4):538–51. 10.1016/j.bbmt.2016.09.011. - DOI - PMC - PubMed

Publication types

Associated data

LinkOut - more resources